Optic Neuropathy

Optic neuropathy develops through several distinct biological mechanisms depending on the type. All pathways ultimately lead to the same final result: the death of retinal ganglion cells—the nerve cells whose fibers make up the optic nerve—and the permanent loss of the visual signals they carried. Understanding the mechanism helps determine the right treatment.

In glaucomatous optic neuropathy, retinal ganglion cells die through a combination of mechanical stress from elevated eye pressure and inadequate blood flow to the optic nerve head. The trabecular meshwork—the eye’s primary drainage structure—becomes less efficient with age, causing aqueous fluid to build up and raise pressure within the eye (intraocular pressure—IOP). Sustained elevated IOP distorts and collapses the lamina cribrosa, the sieve-like structure through which RGC axons exit the eye, physically compressing nerve fibers and blocking the transport of proteins and nutrients along the axons. In normal-tension glaucoma, vascular factors—poor blood flow regulation at the optic nerve head—drive nerve loss even without elevated pressure. A cascade of molecular damage follows, including mitochondrial dysfunction, oxidative stress, and ultimately programmed cell death (apoptosis) of retinal ganglion cells.

Ischemic optic neuropathy results from sudden loss of blood flow to the optic nerve, causing tissue infarction—the same process that causes a heart attack, but localized to the nerve. In nonarteritic AION, atherosclerosis, hypertension, diabetes, and sleep apnea contribute to small vessel disease in the short posterior ciliary arteries that supply the optic nerve head. A crowded disc anatomy with little cerebrospinal fluid buffer space makes the nerve more vulnerable to any reduction in perfusion pressure. In arteritic AION, giant cell arteritis—an inflammatory disease targeting medium and large vessels—causes inflammation and occlusion of the blood supply to the optic nerve, leading to more severe and often bilateral infarction.

In inflammatory optic neuritis, autoreactive immune cells—including T-cells and B-cells—attack the myelin sheath that insulates the optic nerve fibers. This disrupts the saltatory conduction of nerve signals, causing vision to deteriorate. In MS-associated optic neuritis, T-cells primed against myelin cross the blood-brain barrier and initiate inflammation along the optic nerve. In NMOSD, antibodies against the AQP4 water channel trigger complement activation and destruction of the supportive astrocyte cells of the optic nerve, causing more severe and less recoverable damage than typical MS-related neuritis. In MOG-IgG disease, antibodies target the myelin coating more directly and cause recurrent inflammation that is highly steroid-responsive but tends to return when steroids are withdrawn.

In Leber hereditary optic neuropathy and autosomal dominant optic atrophy, mutations impair the mitochondria—the energy-producing organelles inside cells—specifically in retinal ganglion cells, which have exceptionally high energy demands given the length and density of their axons. In LHON, mutations in the mitochondrial DNA disrupt Complex I of the electron transport chain, reducing adenosine triphosphate (ATP) production and triggering reactive oxygen species that cause RGC apoptosis. The unmyelinated portion of the optic nerve at the disc is thought to be particularly vulnerable. In OPA1-related optic atrophy, the OPA1 protein, which maintains the inner mitochondrial membrane structure, is dysfunctional, causing mitochondrial fragmentation and progressive RGC loss.

Risk factors vary by the specific type of optic neuropathy, but several broadly applicable factors increase the overall likelihood of developing nerve damage.

• Elevated intraocular pressure: the most important modifiable risk factor. The higher and longer the IOP elevation, the greater the nerve damage over time.
• Older age: The prevalence of POAG rises steeply after age 60 and continues to increase with each decade.
• African or Hispanic descent: People of African descent are at significantly higher risk for POAG, develop it earlier, and progress more rapidly. Hispanic Americans also face elevated risk.
• Family history of glaucoma: Having a first-degree relative with glaucoma approximately doubles the risk.
• Thin central cornea: A cornea thinner than average is associated with higher risk of glaucomatous damage, independent of measured IOP.
• Myopia (nearsightedness): High myopia is an independent risk factor for POAG and for NTG.
• Diabetes mellitus: This is associated with approximately double the risk of open-angle glaucoma.

• Age over 50: NAION is rare under age 50 and becomes much more common with advancing age.
• Small, crowded optic disc anatomy (disc-at-risk): A disc with little or no central cup provides little anatomical reserve when the nerve swells from ischemia.
• Cardiovascular risk factors: Hypertension, diabetes, hyperlipidemia, obesity, and smoking all damage small blood vessels, increasing the risk of NAION.
• Obstructive sleep apnea: This is a strong and often underrecognized risk factor for NAION, likely through nocturnal hypoxia and blood pressure fluctuation.
• Phosphodiesterase-5 inhibitor use: Sildenafil (Viagra®) and related medications have been associated with NAION in men with pre-existing disc-at-risk anatomy.
• Age over 60 with new headache, jaw claudication, or scalp tenderness: These are warning signs of giant cell arteritis (the cause of AAION), which is a medical emergency.

Screening strategies differ significantly by the type of optic neuropathy. For glaucoma—the most common form—population-wide screening is not currently implemented in most countries, but targeted screening of high-risk groups is strongly recommended. Adults over age 40 should have a comprehensive eye exam, including measurement of IOP, evaluation of the optic disc, and visual field testing, every one to two years. Those with risk factors—including a family history of glaucoma, African or Hispanic descent, elevated IOP, or thin corneas—should begin screening earlier and be examined more frequently. Glaucoma can be present for years with normal IOP in the normal-tension form, so disc examination and visual field testing are essential components of screening beyond IOP measurement alone.

For ischemic optic neuropathy, the most important screening act is recognizing giant cell arteritis early. Any adult over age 60 who develops sudden vision loss in one eye combined with headache, scalp tenderness, jaw pain when chewing, fever, or unexplained fatigue should have blood tests for inflammatory markers—particularly erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)—and should be referred urgently to an ophthalmologist. These tests, along with temporal artery biopsy, confirm or exclude the diagnosis. For toxic optic neuropathies, patients starting medications with known optic nerve toxicity—such as ethambutol, linezolid, or amiodarone—should have a baseline eye exam and follow-up evaluations at regular intervals during treatment. Patients with known hereditary risk (maternal family history of LHON, or a family member with OPA1 optic atrophy) may benefit from genetic testing and baseline ophthalmological assessment even before symptoms develop.

The hallmark of all optic neuropathies is vision loss—but the pattern, speed of onset, location in the visual field, and associated features vary considerably by type. Because the optic nerve carries information from the entire visual field, damage can affect central vision, peripheral vision, or both, depending on which nerve fibers are most affected. An important objective sign that is present in virtually all unilateral or asymmetric optic neuropathies is a relative afferent pupillary defect (RAPD)—also called a Marcus Gunn pupil—in which the pupil of the affected eye does not constrict as strongly when a light is shone directly into it compared to the unaffected eye. Detecting an RAPD confirms that the visual loss is due to optic nerve rather than retinal disease.

• In glaucomatous optic neuropathy: The most common pattern is insidious loss of peripheral (side) vision that is almost never noticed by the patient in the early to middle stages. Many people with moderate glaucoma have no awareness of vision loss on either side. Central vision is typically preserved until late in the disease. By the time a person notices anything wrong, significant and irreversible nerve damage has already occurred. This is why glaucoma is called the silent thief of sight. Acute angle-closure glaucoma is the exception—it causes sudden severe eye pain, headache, nausea, halos around lights, and dramatically blurred vision, and is a medical emergency.
• In ischemic optic neuropathy: In NAION and AAION, vision loss is typically sudden, often noticed upon waking, and involves a specific pattern—either the upper or lower half of the visual field (called an altitudinal field defect)—because the blood supply is lost to one portion of the optic disc. Central vision may or may not be affected. Some patients describe a gray or dark shadow over the top or bottom of what they see. AAION is typically more severe and may cause complete loss of light perception in the affected eye.
• In optic neuritis: Vision loss develops rapidly over hours to days, typically affecting one eye. The loss often involves central vision, causing blurring or a central dark spot. Color vision is frequently more affected than black-and-white visual acuity—colors appear faded or washed out, particularly red. Eye pain that is worse with eye movement is present in about 90% of MS-associated optic neuritis cases and is a distinctive feature that helps identify the diagnosis. Most vision recovers over weeks to months in MS-related optic neuritis. NMOSD-associated optic neuritis is typically more severe and recovers less completely.
• In hereditary optic neuropathy: LHON typically causes painless, subacute central vision loss in one eye, followed by the other eye weeks to months later. Both eyes eventually reach a similar level of severe central vision loss, with peripheral vision generally preserved. Affected individuals are often young men in their teens to thirties. Autosomal dominant optic atrophy causes slowly progressive bilateral central vision loss beginning in childhood, and is often first noticed when a child struggles with reading or fine visual tasks.

• Reduced visual acuity: This presents as blurring of central vision, which may range from mild to severe depending on the type and extent of nerve damage.
• Visual field loss: This is a loss of a portion of the normal field of vision, ranging from peripheral field loss (glaucoma) to central loss (optic neuritis, LHON) to altitudinal (upper or lower half) loss (ischemic optic neuropathy).
• Color vision impairment: particularly red-green discrimination. Colors appear faded or desaturated in the affected eye. This is often out of proportion to the degree of acuity loss and is a sensitive early sign of optic nerve disease.
• Relative afferent pupillary defect (RAPD): When a light is swung between the two eyes, the affected eye’s pupil dilates rather than constricts (or constricts less briskly). This is the objective bedside test for optic nerve dysfunction and is detectable by an examiner even when the patient cannot describe their symptoms precisely.
• Contrast sensitivity loss: difficulty distinguishing objects from their backgrounds, even when standard letter-chart vision appears relatively normal. This impairs driving, reading, and navigating in low-light conditions.
• Pain with eye movement: This is a characteristic of optic neuritis; caused by traction on the inflamed optic nerve sheath by the adjacent extraocular muscles.
• Pallor of the optic disc: whitening of the optic disc (the visible head of the nerve) from loss of nerve fibers, visible during an eye examination. This is a sign of chronic or completed optic nerve damage.

Optic neuropathy is diagnosed by an ophthalmologist—often a neuro-ophthalmologist or glaucoma specialist—through a combination of clinical history, detailed eye examination, imaging, and laboratory or genetic testing, depending on the suspected type. The diagnostic process must first confirm that the optic nerve is the source of vision loss—rather than the retina, lens, or visual cortex—and then identify the specific cause, because treatment varies dramatically between types.

• Visual acuity testing: a standard eye chart test that measures central vision sharpness. In glaucoma, acuity is often normal until late. In optic neuritis and ischemic optic neuropathy, acuity may be moderately or severely reduced.
• Color vision testing: Ishihara color plates or similar tests reveal desaturation of colors, particularly red. Color vision loss out of proportion to acuity loss is a specific indicator of optic nerve disease. Comparing color brightness between the two eyes is a sensitive bedside test.
• Pupillary exam and RAPD testing: The swinging flashlight test evaluates whether both eyes respond equally to light. An RAPD confirms unilateral or asymmetric optic nerve dysfunction. It is one of the most important signs in neuro-ophthalmology.
• Visual field testing (perimetry): Automated static perimetry (Humphrey Visual Field testing) maps the full extent of the patient’s peripheral and central visual field. It identifies and quantifies field loss, tracks progression over time, and characterizes the pattern of loss—which helps identify the type of optic neuropathy present. Glaucomatous field loss typically begins as arcuate or nasal step defects; ischemic optic neuropathy causes altitudinal defects; optic neuritis most often causes central or centrocecal scotomas.
• Slit-lamp and dilated fundus examination: allows direct visualization of the optic disc, its cup-to-disc ratio, any pallor, swelling (papilledema), hemorrhages, or abnormal blood vessels. Disc swelling is seen in optic neuritis and acute ischemic events. Pale cupped discs indicate glaucoma. Pale flat discs suggest past optic neuritis or hereditary atrophy.

• Optical coherence tomography (OCT): a noninvasive scan that uses light to produce cross-sectional images of the retina’s layers. OCT of the retinal nerve fiber layer (RNFL) measures the thickness of RGC axon bundles around the optic disc. Thinning indicates nerve fiber loss and is detectable before visual field changes appear. OCT of the ganglion cell layer measures RGC body loss in the macula. Serial OCT over time allows tracking of progressive fiber loss in glaucoma and assessment of treatment response.
• Magnetic resonance imaging (MRI) of the brain and orbits with gadolinium contrast: essential for evaluation of optic neuritis, compressive optic neuropathy, and when intracranial pathology is suspected. In optic neuritis, the optic nerve enhances with gadolinium contrast due to active inflammation. MRI also identifies demyelinating plaques consistent with MS, or masses compressing the visual pathway. MRI of the orbits specifically evaluates for thyroid eye disease, orbital tumors, and optic nerve sheath meningioma.
• Computed tomography (CT) of the orbits and sinuses: used to assess bony anatomy, orbital fractures in traumatic optic neuropathy, calcified optic nerve sheath meningiomas, and sinus disease. CT angiography is used to evaluate for aneurysm when compressive optic neuropathy is suspected from a vascular cause.
• Fundus fluorescein angiography: a dye injected into the bloodstream and photographed as it passes through the retinal and disc vasculature. Used in ischemic optic neuropathies to assess disc perfusion and identify vascular occlusion.

Treatment for optic neuropathy is highly specific to the underlying cause. Because most optic nerve damage is irreversible, the primary goals of treatment are to stop or slow further loss of nerve fibers, protect any remaining function, and—where possible—recover vision that has been impaired by reversible mechanisms such as inflammation, swelling, or nutritional deficiency. The sooner treatment begins, the better the chances of preserving useful sight. Your doctor will tailor treatment to your specific diagnosis, the degree of vision loss, and the pace of progression.

The only proven treatment strategy for glaucoma is lowering intraocular pressure. Even in normal-tension glaucoma—where IOP is not elevated—reducing IOP further protects the optic nerve. Treatment begins with the least invasive effective option and escalates as needed.

• Prostaglandin analogs: the most commonly prescribed first-line glaucoma drops. Latanoprost (Xalatan®), bimatoprost (Lumigan®), travoprost (Travatan Z®), and tafluprost (Zioptan®) increase fluid outflow from the eye and lower IOP by 25 to 35%. Applied once daily at bedtime. Side effects include gradual darkening of the iris and eyelid skin with long-term use.
• Beta-blocker eye drops: timolol (Timoptic®), betaxolol (Betoptic®). Reduce aqueous fluid production. Used twice daily. Contraindicated in asthma and certain heart conditions.
• Alpha-2 agonists: brimonidine (Alphagan®). Reduces aqueous production and may have neuroprotective properties. Used two to three times daily.
• Carbonic anhydrase inhibitors: topical: dorzolamide (Trusopt®), brinzolamide (Azopt®). Oral: acetazolamide (Diamox®), for acute angle-closure emergencies. Reduce aqueous production.
• Rho kinase (ROCK) inhibitors: netarsudil (Rhopressa®), a newer class approved in 2017 that increases trabecular outflow and reduces episcleral venous pressure. Combined with latanoprost in Rocklatan®.
• Fixed-combination drops: multiple agents combined in one bottle to simplify dosing. brimonidine and timolol (Combigan®), dorzolamide and timolol, netarsudil and latanoprost (Rocklatan®).
• Selective laser trabeculoplasty (SLT): a brief, painless in-office laser procedure that improves drainage through the trabecular meshwork. Can lower IOP by 20 to 30% and may be used as first-line therapy or as an adjunct to drops. Effects can last several years, and the procedure can be repeated.
• Laser peripheral iridotomy (LPI): used for angle-closure glaucoma. A laser creates a small hole in the peripheral iris to allow fluid to bypass the blocked drainage angle.
• Minimally invasive glaucoma surgery (MIGS): a growing category of surgical procedures that create new drainage pathways with lower risk than traditional surgery. Includes iStent inject® W, Hydrus® Microstent, and goniotomy procedures, often combined with cataract surgery.
• Trabeculectomy and glaucoma drainage devices: traditional glaucoma surgeries that create a new drainage channel (trabeculectomy) or implant a tube shunt to direct fluid away from the eye. Reserved for advanced or refractory glaucoma.

For NAION, there is currently no proven treatment that restores vision that has already been lost. Management focuses on identifying and controlling vascular risk factors—blood pressure, blood sugar, cholesterol, and sleep apnea—to reduce the risk of a second episode in the same eye or involvement of the second eye. The second eye is affected in approximately 15 to 20% of NAION patients over five years. For AAION, treatment is an emergency. High-dose intravenous (IV) corticosteroids—typically methylprednisolone 1,000 mg daily for three days—must be started immediately upon clinical suspicion, before biopsy results are available. Oral prednisone (1 mg/kg/day) continues for months and is tapered slowly. Tocilizumab (Actemra®), an IL-6 receptor antagonist, was U.S. Food and Drug Administration (FDA)-approved in 2017 for giant cell arteritis and is used as a steroid-sparing agent to maintain remission and allow faster tapering of prednisone.

For MS-associated optic neuritis, the standard treatment for moderate-to-severe episodes is high-dose intravenous methylprednisolone (1,000 mg per day for three to five days), which speeds visual recovery but does not ultimately improve the degree of final recovery compared to no treatment. Mild optic neuritis may be observed without IV steroids. Following an episode of optic neuritis with MS-like MRI lesions, neurologists discuss starting a disease-modifying therapy to reduce the risk of future MS relapses and long-term disability accumulation. For NMOSD-associated optic neuritis, acute attacks are treated with IV steroids and often plasma exchange (plasmapheresis). Long-term prevention of relapses requires immunosuppressive therapy—options now include eculizumab (Soliris®), satralizumab (Enspryng®), inebilizumab (Uplizna®), and ublituximab (Briumvi®), all FDA-approved specifically for AQP4-positive NMOSD. For MOG-IgG optic neuritis, acute treatment with IV steroids is effective, but slow oral steroid tapering afterward is often needed to prevent relapse, which occurs in the majority of patients. Long-term immunosuppression with azathioprine, mycophenolate mofetil, or rituximab is used in relapsing cases.

For Leber hereditary optic neuropathy, idebenone (Raxone®) is approved in Europe for treatment of LHON and is used in the United States on a compassionate use basis. It is a synthetic analog of CoQ10 that helps bypass the Complex I defect in the mitochondrial respiratory chain. The greatest benefit is seen in patients treated within the first year of symptom onset who still have some residual vision. Lenadogene nolparvovec (Lumevoq®) is a gene therapy delivered by direct injection into the vitreous of the eye, approved in Europe for LHON caused by the MT-ND4 mutation (the most common LHON mutation). It delivers a functional copy of the ND4 gene into retinal ganglion cells via an adeno-associated virus (AAV) vector. Clinical trials have shown meaningful visual improvement in treated patients compared to natural history. FDA review is ongoing. For OPA1-related optic atrophy, there is currently no approved neuroprotective treatment. Management involves low-vision rehabilitation, monitoring for associated hearing loss and neurological features, and genetic counseling for family members.

The cornerstone of treatment is identifying and removing the causative agent—stopping the toxic medication or correcting the nutritional deficiency. For vitamin B12 deficiency, intramuscular B12 injections are given initially and then maintained with oral or intramuscular supplementation. Recovery of vision is often substantial if treatment begins before permanent axonal loss occurs. For ethambutol toxicity, the drug should be stopped immediately when visual symptoms develop; some recovery occurs but is not guaranteed. Alcohol cessation and nutritional rehabilitation are essential for tobacco-alcohol amblyopia.